These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12600206)

  • 1. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain.
    Butler JS; Loh SN
    Biochemistry; 2003 Mar; 42(8):2396-403. PubMed ID: 12600206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zn(2+)-dependent misfolding of the p53 DNA binding domain.
    Butler JS; Loh SN
    Biochemistry; 2007 Mar; 46(10):2630-9. PubMed ID: 17297920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folding and misfolding mechanisms of the p53 DNA binding domain at physiological temperature.
    Butler JS; Loh SN
    Protein Sci; 2006 Nov; 15(11):2457-65. PubMed ID: 17001034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Zn2+ on DNA recognition and stability of the p53 DNA-binding domain.
    Duan J; Nilsson L
    Biochemistry; 2006 Jun; 45(24):7483-92. PubMed ID: 16768444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
    Lubin DJ; Butler JS; Loh SN
    J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic partitioning during folding of the p53 DNA binding domain.
    Butler JS; Loh SN
    J Mol Biol; 2005 Jul; 350(5):906-18. PubMed ID: 15982667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectroscopic determination of the binding affinity of zinc to the DNA-binding domains of nuclear hormone receptors.
    Payne JC; Rous BW; Tenderholt AL; Godwin HA
    Biochemistry; 2003 Dec; 42(48):14214-24. PubMed ID: 14640689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural studies on a protein-binding zinc-finger domain of Eos reveal both similarities and differences to classical zinc fingers.
    Westman BJ; Perdomo J; Matthews JM; Crossley M; Mackay JP
    Biochemistry; 2004 Oct; 43(42):13318-27. PubMed ID: 15491138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metal-dependent folding and stability of nuclear hormone receptor DNA-binding domains.
    Low LY; Hernández H; Robinson CV; O'Brien R; Grossmann JG; Ladbury JE; Luisi B
    J Mol Biol; 2002 May; 319(1):87-106. PubMed ID: 12051939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
    Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
    Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of metal ion on the structural stability of tumour suppressor protein p53 DNA-binding domain.
    Xue Y; Wang S; Feng X
    J Biochem; 2009 Aug; 146(2):193-200. PubMed ID: 19346293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific DNA binding by different classes of human p53 mutants.
    Rolley N; Butcher S; Milner J
    Oncogene; 1995 Aug; 11(4):763-70. PubMed ID: 7651740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docking study and free energy simulation of the complex between p53 DNA-binding domain and azurin.
    De Grandis V; Bizzarri AR; Cannistraro S
    J Mol Recognit; 2007; 20(4):215-26. PubMed ID: 17703463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication protein A interactions with DNA: differential binding of the core domains and analysis of the DNA interaction surface.
    Wyka IM; Dhar K; Binz SK; Wold MS
    Biochemistry; 2003 Nov; 42(44):12909-18. PubMed ID: 14596605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of the human p53 core domain in the absence of DNA.
    Wang Y; Rosengarth A; Luecke H
    Acta Crystallogr D Biol Crystallogr; 2007 Mar; 63(Pt 3):276-81. PubMed ID: 17327663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of the human LRH-1 DBD-DNA complex reveals Ftz-F1 domain positioning is required for receptor activity.
    Solomon IH; Hager JM; Safi R; McDonnell DP; Redinbo MR; Ortlund EA
    J Mol Biol; 2005 Dec; 354(5):1091-102. PubMed ID: 16289203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of mutations on peptide models of the DNA binding helix of p53: evidence for a correlation between structure and tumorigenesis.
    Trulson JA; Millhauser GL
    Biopolymers; 1999 Mar; 49(3):215-24. PubMed ID: 9990839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops.
    Stros M; Muselíková-Polanská E; Pospísilová S; Strauss F
    Biochemistry; 2004 Jun; 43(22):7215-25. PubMed ID: 15170359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation.
    Ishimaru D; Ano Bom AP; Lima LM; Quesado PA; Oyama MF; de Moura Gallo CV; Cordeiro Y; Silva JL
    Biochemistry; 2009 Jul; 48(26):6126-35. PubMed ID: 19505151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.